Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes (Q34718540)

4 August 2017

Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes (English)

1 reference

4 August 2017

1 reference

7

Michael J Rybak

1 reference

4 August 2017

Susan L Davis

1

1 reference

4 August 2017

Peggy S McKinnon

2

1 reference

4 August 2017

Levi M Hall

3

1 reference

4 August 2017

George Delgado

4

1 reference

4 August 2017

Warren Rose

5

1 reference

4 August 2017

Robert F Wilson

6

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

4 August 2017

1 reference

4 August 2017

27

1 reference

4 August 2017

12

1 reference

4 August 2017

1611-1618

1 reference

Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection

4 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Prediction Model to Identify Patients WithStaphylococcus aureusBacteremia at Risk for Methicillin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

The importance of bactericidal drugs: future directions in infectious disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.12.1611

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.12.1611

1 reference

4 August 2017

1 reference